Affymax $50M offering, as Hematide still on track for Q2 US filing
This article was originally published in Scrip
Executive Summary
The biopharmaceutical company Affymax is trying to raise $50 million through a secondary public offering in order to support development and marketing of its investigational erythropoiesis-stimulating agent (ESA), Hematide (peginesatide). The compound is partnered with Takeda, and following a meeting the two companies had in November with the US FDA, they believe that data from the completed trials of the compound are sufficient for an NDA filing for the treatment of anaemia in chronic renal failure patients on dialysis in the second quarter. The prospectus accompanying the offering confirms this submission schedule.